My takeaways from new analysis of the CheckMate 9ER trial - Sergio Cifuentes Canaval
ESMO Open Tom Powles Mauricio Burotto Andrea Apolo, M.D. Maite Bourlon Toni Choueiri, MD Robert Motzer MD
oncodaily.com/62648.html

#Cancer #ClinicalTrials #Cancer Research #OncoDaily #Oncology

My takeaways from new analysis of the CheckMate 9ER trial
Thanks OncoDaily for this open space.

oncodaily.com/insight/62648.…

💥The 2024 #TECLounge Career Conversations 👥sign up is OPEN! All #TECLounge attendees can sign-up for a 25-minute Career Conversation on a variety of training and career development topics! 🔥
signupgenius.com/go/30E0A45A9A9…
Ana I. Velázquez Mañana, MD MSc (she/her/ella) Ramy Sedhom, MD Fernando Diaz, MD Jacob J. Adashek, DO

Thrilled to share my insights on colorectal cancer treatment controversies at Sociedad Mexicana de Oncología, A.C. Residents' Session!
Engaging discussion on adjuvant timing with oncology, surgical oncology, and radiation oncology residents.

Trainee & Early Career Oncologists:

Sessions and networking events for #ASCO24 ASCO are here!!!⬇️

Plan in advanced and get a ☕️ at the new, larger location of the ASCOTECAG lounge! (Hall C)

society.asco.org/sites/new-www.…

Jacob J. Adashek, DO Fernando Diaz, MD Aakash Desai, MD, MPH

ctDNA for predicting response and prognosis in HER2-BC in NAC - Sergio Cifuentes
Dr. Laura Esserman Angie DeMichele, MD, MSCE, FASCO Laura VAN T VEER
oncodaily.com/61305.html

#BreastCancer #Cancer #OncoDaily #Oncology

Update CheckMate 9ER
- PFS: 16.6 m vs 8.4 m
- OS: 49.5 m vs 35.5 m (HR 0.70; 95% CI 0.56-0.87)
- CR: 13% vs 5%
- ORR: 56% (50-62%) vs 28% (23-33%)
- mDoR: 22.1 m vs 16.1 m
🟠 Benefit in intermediate/poor
🇲🇽 Mexican Participation 35%

OncoDaily

👉🏼 doi.org/10.1016/j.esmo…

💡 ctDNA for predicting response and prognosis in HER2-BC in NAC.
👩🏽 HR+: 145 and TNBC 138
🔺 TNBC: ctDNA have correlation with RCB and DFRS
🔺 HR+: ctDNA have correlation with DRFS

OncoDaily
OncoAlert

📄 doi.org/10.1158/1078-0…

ASCO Educational Book

NSCLC Metastatic Without Oncogenic Alterations

🔹️Monotherapy? Combination therapy?

🔹️How long should the treatment duration be?

🔹️How do we integrate ADCs into treatment?

💥For details and more, it's a great read👇

OncoAlert…

I had the privilege of attending the ESMO Preceptorship on Breast Cancer in São Paulo 🇧🇷 .
Grateful for the knowledge gained and share with wonderful colleagues!

ESMO - Eur. Oncology

🫁 Osimertinib + LT for 🧠mets in EGFRm NSCLC.
🅰️ 121 patients with EGFRm (19del or L858R)
☢️ 45 in Osi+LT vs 76 in Osi alone
✅ OS: Osi+LT group NR vs. Osi alone 31.2 m
🔺 HR for OS: 0.37
🧠 HR for CNS-PFS 0.36

OncoDaily
OncoAlert

👉🏼 doi.org/10.1016/j.lung…

My insights on a recent study Keynote A18 from The Lancet, Domenica Lorusso and Ana Oaknin - Sergio Cifuentes
The Lancet
oncodaily.com/52884.html

#AdjuvantPembrolizumab #Cancer #KEYNOTEA18 #OncoDaily #Oncology #RecurrentRCC

📣 Excited to share that I'll be one of the invited residents at the session on Controversies in #CRC Treatment!

🔑 I'll be discussing the controversy between administering three months of adjuvant therapy versus six months.

👉🏽 Hope to see you there!

Sociedad Mexicana de Oncología, A.C.

My insights on a recent study #KeynoteA18  from The Lancet , Domenica Lorusso and Ana Oaknin

Always striving to stay updated and contribute to the latest research in the field.

OncoDaily

📄 oncodaily.com/insight/51894.…

Today this editorial its more relevant on managing recurrent RCC after adjuvant pembrolizumab.

With positive results from KN 564 in adjuvant therapy for RCC, it's crucial to refine patient care strategies post-adjuvant IO.

Maite Bourlon Toni Choueiri, MD

dailynews.ascopubs.org/do/using-clini…

💡 KEYNOTE-A18
✅ Pembrolizumab + CRT in LACC
✅ mPFS NR in pembrolizumab group

✅ 24m PFS: 68% vs 57%
🔺 Pembrolizumab + CRT led to a 30% reduction in DR
🔺Os at 24m: 87% vs 81%

🟠 Grade 3 or higher AE: 75% vs 69%

OncoAlert
OncoDaily

📄 thelancet.com/journals/lance…

🗣️🌍👩🏻‍⚕️👨🏻‍⚕️ ASCO JCO Global Oncology published Competencies for Global Oncology Training

🔸Knowledge & Skills need in global health & cancer specific care
🔹 Understand disparities, define resources in LMICs & promote international collaboration

#globaloncology OncoAlert OncoDaily

Sharing recent insights on the impact of Alectinib in adjuvant therapy for non-small cell lung cancer (NSCLC).

Thanks OncoDaily for open this space.

oncodaily.com/insight/48236.…

🌟 ALINA: Alectinib vs. CHT
🎉 76% lower risk of disease recurrence or death with alectinib.
✅ HR for DFS: 0.24
🧠 HR for CNS: 0.22
🔻 Dose reduction, interruption, or discontinuation reported in 25.8%, 27.3%, and 5.5%

OncoAlert NEJM

👉🏽 nejm.org/doi/full/10.10…